| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
|
Lancet
|
2009
|
5.82
|
|
2
|
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
|
J Clin Oncol
|
2008
|
5.11
|
|
3
|
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
|
J Clin Oncol
|
2005
|
4.33
|
|
4
|
Aurora kinases as anticancer drug targets.
|
Clin Cancer Res
|
2008
|
2.92
|
|
5
|
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
|
J Clin Oncol
|
2008
|
2.85
|
|
6
|
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
|
J Thorac Oncol
|
2015
|
2.80
|
|
7
|
Natural history of stage I non-small cell lung cancer: implications for early detection.
|
Chest
|
2007
|
2.78
|
|
8
|
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
|
J Clin Oncol
|
2009
|
2.73
|
|
9
|
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
|
J Clin Oncol
|
2008
|
2.64
|
|
10
|
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
|
J Clin Oncol
|
2013
|
2.59
|
|
11
|
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
|
J Clin Oncol
|
2009
|
2.54
|
|
12
|
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.
|
J Clin Oncol
|
2005
|
2.19
|
|
13
|
Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials.
|
J Clin Oncol
|
2005
|
2.10
|
|
14
|
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.
|
J Clin Oncol
|
2002
|
2.07
|
|
15
|
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.
|
Arch Intern Med
|
2008
|
1.79
|
|
16
|
Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
|
J Natl Cancer Inst
|
2002
|
1.78
|
|
17
|
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.70
|
|
18
|
An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
|
Cancer J
|
2004
|
1.68
|
|
19
|
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
|
Urology
|
2010
|
1.65
|
|
20
|
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
|
Clin Lung Cancer
|
2006
|
1.61
|
|
21
|
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
|
Clin Cancer Res
|
2008
|
1.60
|
|
22
|
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
|
Clin Cancer Res
|
2012
|
1.53
|
|
23
|
Epidermal growth factor receptor inhibition in lung cancer: status 2012.
|
J Thorac Oncol
|
2013
|
1.50
|
|
24
|
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
|
Cancer Chemother Pharmacol
|
2009
|
1.47
|
|
25
|
Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign.
|
Cancer
|
2008
|
1.47
|
|
26
|
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
|
J Clin Oncol
|
2007
|
1.46
|
|
27
|
A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma.
|
Clin Cancer Res
|
2008
|
1.43
|
|
28
|
Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group.
|
J Clin Oncol
|
2005
|
1.41
|
|
29
|
Phase I trial of edatrexate in advanced breast and other cancers.
|
Cancer Invest
|
2002
|
1.39
|
|
30
|
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
|
J Thorac Oncol
|
2006
|
1.39
|
|
31
|
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
|
J Clin Oncol
|
2008
|
1.38
|
|
32
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
J Clin Oncol
|
2012
|
1.37
|
|
33
|
Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care.
|
J Pain Symptom Manage
|
2004
|
1.33
|
|
34
|
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
|
Clin Lung Cancer
|
2007
|
1.30
|
|
35
|
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
|
J Clin Oncol
|
2005
|
1.29
|
|
36
|
Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
|
J Thorac Oncol
|
2010
|
1.29
|
|
37
|
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
|
Anticancer Drugs
|
2009
|
1.26
|
|
38
|
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
|
J Clin Oncol
|
2006
|
1.25
|
|
39
|
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
|
Clin Genitourin Cancer
|
2007
|
1.23
|
|
40
|
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.
|
Cancer Res
|
2008
|
1.21
|
|
41
|
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
|
J Thorac Oncol
|
2009
|
1.21
|
|
42
|
Incorporating bortezomib into the treatment of lung cancer.
|
Clin Cancer Res
|
2007
|
1.17
|
|
43
|
The tissue is the issue: personalized medicine for non-small cell lung cancer.
|
Clin Cancer Res
|
2010
|
1.16
|
|
44
|
Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
|
J Thorac Oncol
|
2009
|
1.16
|
|
45
|
Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.
|
J Thorac Oncol
|
2014
|
1.11
|
|
46
|
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
|
J Thorac Oncol
|
2009
|
1.09
|
|
47
|
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
|
J Thorac Oncol
|
2010
|
1.07
|
|
48
|
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
|
Clin Cancer Res
|
2005
|
1.07
|
|
49
|
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
|
J Clin Oncol
|
2010
|
1.06
|
|
50
|
Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial.
|
Clin Lung Cancer
|
2006
|
1.06
|
|
51
|
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
|
J Clin Oncol
|
2006
|
1.06
|
|
52
|
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
|
J Thorac Oncol
|
2009
|
1.06
|
|
53
|
Treatment of extensive small cell lung cancer.
|
Hematol Oncol Clin North Am
|
2004
|
1.05
|
|
54
|
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
|
Clin Cancer Res
|
2011
|
1.03
|
|
55
|
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
|
Clin Cancer Res
|
2003
|
1.02
|
|
56
|
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
|
Lung Cancer
|
2003
|
1.01
|
|
57
|
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
|
Lung Cancer
|
2003
|
1.00
|
|
58
|
Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819.
|
Clin Cancer Res
|
2012
|
1.00
|
|
59
|
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
|
Clin Lung Cancer
|
2004
|
0.99
|
|
60
|
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
|
Clin Cancer Res
|
2004
|
0.99
|
|
61
|
Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
|
J Clin Oncol
|
2005
|
0.99
|
|
62
|
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
|
J Thorac Oncol
|
2006
|
0.97
|
|
63
|
Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.
|
Clin Lung Cancer
|
2008
|
0.97
|
|
64
|
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
|
Cancer
|
2004
|
0.96
|
|
65
|
Progress in small-cell lung cancer: the lowest common denominator.
|
J Clin Oncol
|
2008
|
0.95
|
|
66
|
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
|
J Clin Oncol
|
2009
|
0.94
|
|
67
|
Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy.
|
Ann N Y Acad Sci
|
2004
|
0.94
|
|
68
|
Docetaxel in non-small cell lung cancer: a review.
|
Expert Opin Pharmacother
|
2003
|
0.94
|
|
69
|
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
|
J Thorac Oncol
|
2012
|
0.94
|
|
70
|
Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies.
|
Cancer Invest
|
2003
|
0.93
|
|
71
|
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
|
J Clin Oncol
|
2009
|
0.92
|
|
72
|
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
|
Cancer Chemother Pharmacol
|
2011
|
0.92
|
|
73
|
HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial.
|
Cancer
|
2002
|
0.92
|
|
74
|
Non-small-cell lung cancer: then and now.
|
J Clin Oncol
|
2013
|
0.92
|
|
75
|
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
|
J Thorac Oncol
|
2011
|
0.91
|
|
76
|
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
|
Am J Clin Oncol
|
2008
|
0.91
|
|
77
|
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
|
J Thorac Oncol
|
2011
|
0.91
|
|
78
|
Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy.
|
J Thorac Oncol
|
2013
|
0.91
|
|
79
|
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
|
Semin Oncol
|
2004
|
0.90
|
|
80
|
Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
|
J Clin Oncol
|
2004
|
0.90
|
|
81
|
Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6.
|
J Thorac Oncol
|
2007
|
0.90
|
|
82
|
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
|
Invest New Drugs
|
2010
|
0.90
|
|
83
|
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
|
Clin Cancer Res
|
2006
|
0.90
|
|
84
|
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
|
Clin Cancer Res
|
2004
|
0.90
|
|
85
|
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
|
J Thorac Oncol
|
2008
|
0.89
|
|
86
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
Lung Cancer
|
2012
|
0.89
|
|
87
|
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.
|
Cancer
|
2010
|
0.89
|
|
88
|
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.89
|
|
89
|
Aurora kinase inhibitors: a new class of targeted drugs in cancer.
|
Clin Lung Cancer
|
2006
|
0.89
|
|
90
|
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
|
Clin Lung Cancer
|
2008
|
0.88
|
|
91
|
Novel agents in the treatment of lung cancer: conference summary statement.
|
Clin Cancer Res
|
2004
|
0.88
|
|
92
|
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
|
J Thorac Oncol
|
2008
|
0.88
|
|
93
|
Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.
|
J Thorac Oncol
|
2015
|
0.87
|
|
94
|
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
|
Cancer Invest
|
2007
|
0.87
|
|
95
|
Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027).
|
J Thorac Oncol
|
2006
|
0.87
|
|
96
|
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
|
Clin Genitourin Cancer
|
2009
|
0.86
|
|
97
|
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
|
Br J Haematol
|
2011
|
0.86
|
|
98
|
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
|
Anticancer Drugs
|
2005
|
0.86
|
|
99
|
Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience.
|
Ther Adv Med Oncol
|
2011
|
0.85
|
|
100
|
Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.
|
Clin Lung Cancer
|
2006
|
0.85
|
|
101
|
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.
|
Cancer
|
2012
|
0.85
|
|
102
|
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).
|
Cancer
|
2014
|
0.84
|
|
103
|
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
|
Invest New Drugs
|
2007
|
0.84
|
|
104
|
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
|
Cancer Chemother Pharmacol
|
2011
|
0.84
|
|
105
|
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
|
Cancer Chemother Pharmacol
|
2003
|
0.83
|
|
106
|
Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer".
|
J Thorac Oncol
|
2015
|
0.83
|
|
107
|
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
|
J Thorac Oncol
|
2015
|
0.83
|
|
108
|
Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells.
|
Radiat Res
|
2004
|
0.83
|
|
109
|
Antisense oligonucleotides in the treatment of non-small-cell lung cancer.
|
Clin Lung Cancer
|
2003
|
0.83
|
|
110
|
Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
|
J Clin Oncol
|
2006
|
0.82
|
|
111
|
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.
|
Clin Lung Cancer
|
2013
|
0.82
|
|
112
|
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium.
|
J Cancer Res Clin Oncol
|
2007
|
0.82
|
|
113
|
Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
|
Curr Opin Oncol
|
2009
|
0.82
|
|
114
|
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
|
J Cancer Res Clin Oncol
|
2014
|
0.82
|
|
115
|
Non-small-cell lung cancer progression after first-line chemotherapy.
|
Curr Treat Options Oncol
|
2002
|
0.82
|
|
116
|
First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.
|
J Thorac Oncol
|
2008
|
0.82
|
|
117
|
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2007
|
0.82
|
|
118
|
Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
|
Clin Lung Cancer
|
2009
|
0.82
|
|
119
|
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
|
Clin Lung Cancer
|
2011
|
0.82
|
|
120
|
CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy.
|
Cancer Res
|
2012
|
0.81
|
|
121
|
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
|
Clin Lung Cancer
|
2006
|
0.81
|
|
122
|
Population-based maximum tolerated dose of irinotecan and carboplatin.
|
Oncology (Williston Park)
|
2003
|
0.81
|
|
123
|
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
|
J Thorac Oncol
|
2011
|
0.81
|
|
124
|
A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer.
|
Front Oncol
|
2013
|
0.81
|
|
125
|
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
|
J Thorac Oncol
|
2013
|
0.81
|
|
126
|
Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved.
|
J Thorac Cardiovasc Surg
|
2003
|
0.81
|
|
127
|
Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.80
|
|
128
|
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
|
Cancer Chemother Pharmacol
|
2009
|
0.80
|
|
129
|
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
|
J Thorac Oncol
|
2007
|
0.79
|
|
130
|
FASTACT-2: but don't act too fast.
|
Lancet Oncol
|
2013
|
0.79
|
|
131
|
Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma.
|
Clin Lung Cancer
|
2013
|
0.79
|
|
132
|
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
|
J Thorac Oncol
|
2007
|
0.79
|
|
133
|
Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study.
|
Invest New Drugs
|
2010
|
0.79
|
|
134
|
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.
|
Int J Clin Oncol
|
2011
|
0.79
|
|
135
|
Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.
|
Clin Cancer Res
|
2005
|
0.79
|
|
136
|
Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
|
Clin Cancer Res
|
2004
|
0.79
|
|
137
|
Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
|
Curr Opin Oncol
|
2011
|
0.78
|
|
138
|
Bronchioloalveolar carcinoma: the "changing face of lung cancer".
|
Clin Lung Cancer
|
2006
|
0.78
|
|
139
|
A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2013
|
0.78
|
|
140
|
SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).
|
J Thorac Oncol
|
2015
|
0.78
|
|
141
|
Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
|
J Thorac Oncol
|
2012
|
0.78
|
|
142
|
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
|
Curr Drug Targets
|
2010
|
0.78
|
|
143
|
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
|
Am J Clin Oncol
|
2006
|
0.78
|
|
144
|
Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer.
|
Clin Lung Cancer
|
2008
|
0.77
|
|
145
|
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
|
Clin Cancer Res
|
2003
|
0.77
|
|
146
|
Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity.
|
Oncology (Williston Park)
|
2008
|
0.77
|
|
147
|
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
|
Clin Lung Cancer
|
2004
|
0.77
|
|
148
|
Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.
|
Clin Lung Cancer
|
2006
|
0.77
|
|
149
|
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
|
Clin Lung Cancer
|
2008
|
0.77
|
|
150
|
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
|
Clin Lung Cancer
|
2009
|
0.77
|
|
151
|
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
|
J Thorac Oncol
|
2008
|
0.77
|
|
152
|
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
|
Clin Lung Cancer
|
2005
|
0.76
|
|
153
|
Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer.
|
Semin Oncol
|
2002
|
0.76
|
|
154
|
Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.
|
Expert Rev Anticancer Ther
|
2012
|
0.76
|
|
155
|
Treatment options for patients with advanced-stage non-small-cell lung cancer: who are the "elderly" and who are the "unfit"?
|
Clin Lung Cancer
|
2005
|
0.75
|
|
156
|
Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line.
|
J Clin Oncol
|
2006
|
0.75
|
|
157
|
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
|
Clin Lung Cancer
|
2009
|
0.75
|
|
158
|
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.
|
Invest New Drugs
|
2013
|
0.75
|
|
159
|
Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.
|
Clin Lung Cancer
|
2008
|
0.75
|
|
160
|
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
|
Cancer Invest
|
2003
|
0.75
|
|
161
|
Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer.
|
J Thorac Oncol
|
2015
|
0.75
|
|
162
|
Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
|
Clin Lung Cancer
|
2005
|
0.75
|
|
163
|
Bevacizumab: optimal dose, schedule, and duration of therapy.
|
Clin Lung Cancer
|
2007
|
0.75
|
|
164
|
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
|
J Thorac Oncol
|
2006
|
0.75
|
|
165
|
Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
|
J Thorac Oncol
|
2007
|
0.75
|
|
166
|
Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer.
|
Clin Lung Cancer
|
2002
|
0.75
|
|
167
|
Predictive molecular markers: has the time come for routine use in lung cancer?
|
J Natl Compr Canc Netw
|
2004
|
0.75
|
|
168
|
Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer.
|
Clin Lung Cancer
|
2002
|
0.75
|
|
169
|
A decade of clinical lung cancer.
|
Clin Lung Cancer
|
2009
|
0.75
|